BioWorld MedTech

Nov. 18, 2016

Disappointed Endologix stumbles as FDA calls for more Nellix EVAS system data

A "disappointed" Endologix Inc. (Nasdaq:ELGX) now is anticipating a second quarter 2018 approval of the Nellix endovascular aneurysm sealing (EVAS) system following the FDA's request for two-year patient follow-up data. Read More

FDA relaxes imaging protocol mandates in 510(k) final for MR

China med tech a hot sector for M&A thanks to regulatory reforms

Limflow wins CE mark for device sparing lower limbs for No-Option patients

What's next now that the JOBS Act is fully implemented?

Financings

Product briefs

Appointments and advancements

MDD's Diagnostics Extra

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Microscopic image of chronic myeloid leukemia

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

BioWorld

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...